{"entity": "publication", "iuid": "4d12b06a01ae4f7aa582051ac121185b", "timestamp": "2026-08-12T05:36:41.565Z", "links": {"self": {"href": "https://publications.scilifelab.se/publication/4d12b06a01ae4f7aa582051ac121185b.json"}, "display": {"href": "https://publications.scilifelab.se/publication/4d12b06a01ae4f7aa582051ac121185b"}}, "title": "Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [11C]PBR28 PET.", "authors": [{"family": "Wallin", "given": "Johan", "initials": "J", "orcid": "0000-0003-0490-9900", "researcher": {"href": "https://publications.scilifelab.se/researcher/1f513ad777614e57a30ce641b9c436ae.json"}}, {"family": "Forsberg", "given": "Anton", "initials": "A", "orcid": "0000-0001-8790-3306", "researcher": {"href": "https://publications.scilifelab.se/researcher/e825af97d4ac433198d14d2c20826ed2.json"}}, {"family": "Svenningsson", "given": "Per", "initials": "P", "orcid": "0000-0001-6727-3802", "researcher": {"href": "https://publications.scilifelab.se/researcher/5199496295334771ba3c5621a83a6f43.json"}}], "type": "journal article", "published": "2025-04-00", "journal": {"title": "Mov Disord", "issn": "1531-8257", "volume": "40", "issue": "4", "pages": "739-744", "issn-l": null}, "abstract": "Dysregulated leukotriene signaling is proposed to be involved in pathogenesis of Parkinson's disease (PD).\n\nThe objective was to examine the safety and tolerability of montelukast, a cysteinyl-leukotriene receptor1 and GPR17 antagonist, in patients with PD. Secondary outcomes were target engagement, effects on PD signs/symptoms, and central neuroinflammation.\n\nFifteen PD patients were recruited to a 12-week open-label trial of 20 mg bi-daily montelukast treatment. Patients underwent ratings with the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS), the Montreal Cognitive Assessment (MoCA), Beck's Depression Inventory (BDI), Parkinson's Disease Questionnaire-39 (PDQ-39), [11C]PBR28-PET, and lumbar punctures before and during montelukast treatment.\n\nAll patients completed the study. Three patients reported loose stool. No serious adverse events related to treatment were reported. MDS-UPDRS-Total scores improved by 6.9 points. Very low levels of montelukast were detected in all cerebrospinal fluid (CSF) samples and resulted in a reduction in inflammation/metabolism markers. [11C]PBR28 binding was lowered in high, but not mixed, affinity binders after montelukast.\n\nMontelukast crosses the blood-brain barrier at very low levels and is well tolerated and safe in PD patients. Preliminary effects on neuroinflammation and clinical scores motivate a future randomized controlled trial (RCT) in PD. \u00a9 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.", "doi": "10.1002/mds.30144", "pmid": "39912596", "labels": {"Swedish Metabolomics Centre": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC12006882"}], "notes": [], "created": "2025-11-18T12:16:32.491Z", "modified": "2025-11-18T12:16:32.623Z"}